HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases

HighTide Therapeutics today announced that the Company will present at the fifth annual NASH-TAG Conference. The hybrid (in-person/virtual) conference, focused on therapeutic agents for non-alcoholic steatohepatitis (NASH) and liver fibrosis

HighTide Therapeutics today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright Global Life Sciences Conference March 9-10, 2021.

SHENZHEN, CHINA and ROCKVILLE, MD, February 1, 2021— HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as Chief Development Officer. Dr. MacConell has over 20 ye

HTD1801 met primary endpoint in Phase 2 trial with statistically significant reduction in liver fat in patients with NASH and diabetes

SHENZHEN, CHINA and ROCKVILLE, MD, October 1, 2020 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company with novel treatments for patientswith non-alcoholic steatohepatitis (NASH) and other chronic liver dis